Pharming Group (PHAR) stock

Worth $9.3BShares as of Dec 31

$13.22

+0.46%

As of Tuesday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score PHAR. It is too thinly traded for a fair Quality Score.

Healthcare · Biotech

NextNov 2026“…immune dysregulation and Phase II topline data in broader CVID patient population expected in November 2026”Trial data · SEC filing · Oct 27

Follow PHAR's news. Pro members can get an alert when Pharming Group files news, and see its trials, share raises, and its CEO's filings.

Get an alert when PHAR files newsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,168 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

What's next for PHAR, and how long its cash lasts

Next step the company has named

Nov 2026“Announced positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation and Phase II topline data in broader CVID patient population expected in November 2026”Trial data · SEC filing · Oct 27

What it means: the first look at a trial’s main results, as the company reports them.

For Pro members: 3 more milestones and 62 filings.

Cash runway Dec 31, 2025 balance sheet

$145M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

For Pro members: every trade.

Get an alert when PHAR files newsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

PHAR's latest filings

A report to the SEC6-K, filed Nov 6
A report to the SEC6-K, filed Oct 27
Annual report20-F, filed Apr 2

21 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why PHAR isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. PHAR trades about 17,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.